Table 3:
Cox proportional hazard model for overall survival
| Variable | Hazard ratio | 95% CI | p-value |
|---|---|---|---|
| Charlson comorbidity index | |||
| 0 | 1 | ||
| 1 | 1.27 | 1.24–1.3 | <0.001 |
| ≥2 | 1.53 | 1.49–1.58 | <0.001 |
|
| |||
| Age | |||
| 60–69 | 1 | ||
| 70–79 | 1.24 | 1.21–1.27 | <0.001 |
| 80–89 | 1.46 | 1.41–1.5 | <0.001 |
| ≥90 | 1.73 | 1.65–1.83 | <0.001 |
|
| |||
| Sex | |||
| Female | 1 | ||
| Male | 1.02 | 1.007–1.04 | 0.006 |
|
| |||
| Race | |||
| White | 1 | ||
| African American | 0.99 | 0.95–1.02 | 0.5 |
| Other | 0.92 | 0.88–0.96 | 0.001 |
|
| |||
| Annual household income * | |||
| ≥$63,000 | 1 | ||
| $48000–62999 | 1.04 | 1.01–1.06 | 0.001 |
| $38000–47999 | 1.06 | 1.03–1.09 | <0.001 |
| <$38,000 | 1.11 | 1.07–1.14 | <0.001 |
|
| |||
| Facility type | |||
| Academic | 1 | ||
| Non-academic | 1.07 | 1.05–1.09 | <0.001 |
|
| |||
| Insurance type | |||
| Private | 1 | ||
| Medicare | 1.17 | 1.08–1.14 | <0.001 |
| None/All | 1.05 | 1.01–1.1 | 0.03 |
|
| |||
| Type of chemotherapy | |||
| No chemotherapy | 1 | ||
| Single agent | 0.5 | 0.49–0.52 | <0.001 |
| Multi agent | 0.38 | 0.37–0.39 | <0.001 |
|
| |||
| Receipt of HCT | |||
| Yes | 1 | ||
| No | 2.14 | 2.01–2.28 | <0.001 |
|
| |||
| Distance traveled (miles) † | |||
| 0–4.9 | 1 | ||
| 5–10.9 | 0.97 | 0.94–0.99 | 0.04 |
| 11–30.9 | 0.98 | 0.95–1.006 | 0.13 |
| ≥31 | 1.009 | 0.98=1.03 | 0.5 |
|
| |||
| Histology | |||
| APL | 1 | ||
| Core binding factor AML | 1.67 | 1.53–1.81 | <0.001 |
| Therapy-related AML/AML MRC | 2.05 | 1.93–2.17 | <0.001 |
| All other | 2.4 | 2.27–2.53 | <0.001 |
|
| |||
| Year of diagnosis | |||
| 2010–2014 | 1 | ||
| 2004–2009 | 1.05 | 1.03–1.07 | <0.001 |
*
based on aggregate census data from the patient’s zip code
†
distance from patients’ residence to the treatment facility
AML- Acute myeloid leukemia; APL- Acute promyelocytic leukemia; CCI- Charlson comorbidity index; CI- Confidence interval; HCT- Hematopoietic cell transplant; MRC-Myelodysplasia related changes